Breckenridge Pharmaceutical, Inc. is recalling approximately 9,193 bottles of Megestrol Acetate Oral Suspension, USP 625 mg/5mL (generic for Megace ES). The recall was initiated because the medication failed stability testing for particle size distribution, which means the drug particles in the suspension may not be the correct size. Consumers who have these specific bottles should contact their healthcare provider or pharmacist for guidance, as the medication may not work as intended.
Incorrect particle size distribution in an oral suspension can affect how the body absorbs the medication, potentially leading to inconsistent dosing or reduced effectiveness of the treatment.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.